Literature DB >> 25326491

RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma.

Xuebo Chen1, Leying Zhang2, Ian Y Zhang2, Junling Liang3, Huaqing Wang4, Mao Ouyang5, Shihua Wu3, Anna Carolina Carvalho da Fonseca6, Lihong Weng7, Yasuhiko Yamamoto8, Hiroshi Yamamoto8, Rama Natarajan9, Behnam Badie2,10.   

Abstract

Interaction of RAGE (the receptor for advanced glycation endproducts) with its ligands can promote tumor progression, invasion, and angiogenesis. Although blocking RAGE signaling has been proposed as a potential anticancer strategy, functional contributions of RAGE expression in the tumor microenvironment (TME) have not been investigated in detail. Here, we evaluated the effect of genetic depletion of RAGE in TME on the growth of gliomas. In both invasive and noninvasive glioma models, animal survival was prolonged in RAGE knockout (Ager(-/-)) mice. However, the improvement in survival in Ager(-/-) mice was not due to changes in tumor growth rate but rather to a reduction in tumor-associated inflammation. Furthermore, RAGE ablation in the TME abrogated angiogenesis by downregulating the expression of proangiogenic factors, which prevented normal vessel formation, thereby generating a leaky vasculature. These alterations were most prominent in noninvasive gliomas, in which the expression of VEGF and proinflammatory cytokines were also lower in tumor-associated macrophages (TAM) in Ager(-/-) mice. Interestingly, reconstitution of Ager(-/-) TAM with wild-type microglia or macrophages normalized tumor vascularity. Our results establish that RAGE signaling in glioma-associated microglia and TAM drives angiogenesis, underscoring the complex role of RAGE and its ligands in gliomagenesis. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25326491      PMCID: PMC4268204          DOI: 10.1158/0008-5472.CAN-14-1240

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium.

Authors:  Ke Zen; Celia X-J Chen; Yi-Tien Chen; Rosemarie Wilton; Yuan Liu
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

2.  Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.

Authors:  Kai Wang; Zhongmin Zhou; Ming Zhang; Liming Fan; Farhad Forudi; Xiaorong Zhou; Wu Qu; A Michael Lincoff; Ann Marie Schmidt; Eric J Topol; Marc S Penn
Journal:  J Pharmacol Exp Ther       Date:  2005-12-20       Impact factor: 4.030

3.  S100B attenuates microglia activation in gliomas: possible role of STAT3 pathway.

Authors:  Leying Zhang; Wei Liu; Darya Alizadeh; Dongchang Zhao; Omar Farrukh; Jeffrey Lin; Sam A Badie; Behnam Badie
Journal:  Glia       Date:  2010-12-29       Impact factor: 7.452

4.  RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.

Authors:  Khin-Mar Myint; Yasuhiko Yamamoto; Toshio Doi; Ichiro Kato; Ai Harashima; Hideto Yonekura; Takuo Watanabe; Harumichi Shinohara; Masayoshi Takeuchi; Koichi Tsuneyama; Noriyoshi Hashimoto; Masahide Asano; Shin Takasawa; Hiroshi Okamoto; Hiroshi Yamamoto
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

5.  Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.

Authors:  Hitoshi Ishiguro; Noboru Nakaigawa; Yasuhide Miyoshi; Kiyoshi Fujinami; Yoshinobu Kubota; Hiroji Uemura
Journal:  Prostate       Date:  2005-06-15       Impact factor: 4.104

6.  Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.

Authors:  K Terada; H Wakimoto; E Tyminski; E A Chiocca; Y Saeki
Journal:  Gene Ther       Date:  2006-04       Impact factor: 5.250

7.  The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.

Authors:  O Hori; J Brett; T Slattery; R Cao; J Zhang; J X Chen; M Nagashima; E R Lundh; S Vijay; D Nitecki
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

8.  Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein.

Authors:  Jong Sung Park; Daiva Svetkauskaite; Qianbin He; Jae-Yeol Kim; Derek Strassheim; Akitoshi Ishizaka; Edward Abraham
Journal:  J Biol Chem       Date:  2003-12-04       Impact factor: 5.157

9.  RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.

Authors:  Maren K Fuentes; Shraddha S Nigavekar; Thiruvengadam Arumugam; Craig D Logsdon; Ann Marie Schmidt; Juliet C Park; Emina H Huang
Journal:  Dis Colon Rectum       Date:  2007-08       Impact factor: 4.585

10.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.

Authors:  Rose Du; Kan V Lu; Claudia Petritsch; Patty Liu; Ruth Ganss; Emmanuelle Passegué; Hanqiu Song; Scott Vandenberg; Randall S Johnson; Zena Werb; Gabriele Bergers
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

View more
  61 in total

1.  Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages.

Authors:  Zhihong Chen; James L Ross; Dolores Hambardzumyan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

2.  Microglia in the tumor microenvironment: taking their TOLL on glioma biology.

Authors:  David H Gutmann
Journal:  Neuro Oncol       Date:  2014-12-18       Impact factor: 12.300

3.  Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.

Authors:  Nathan B Roberts; Aymen Alqazzaz; Jacqueline R Hwang; Xiulan Qi; Achsah D Keegan; Anthony J Kim; Jeffrey A Winkles; Graeme F Woodworth
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

Review 4.  The Role of Checkpoint Inhibitors in Glioblastoma.

Authors:  Kunal Desai; Anne Hubben; Manmeet Ahluwalia
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

5.  Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice.

Authors:  Ian Y Zhang; Hui Zhou; Huili Liu; Leying Zhang; Hang Gao; Shunan Liu; Yanyan Song; Darya Alizadeh; Hongwei Holly Yin; Raju Pillai; Behnam Badie
Journal:  Clin Cancer Res       Date:  2020-02-04       Impact factor: 12.531

6.  Establishment of S100A8 Transgenic Rats to Understand Innate Property of S100A8 and Its Immunological Role.

Authors:  Kohki Okada; Hiroshi Itoh; Yasuhiko Kamikubo; Souichi Adachi; Masaki Ikemoto
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

Review 7.  The role of microglia and macrophages in glioma maintenance and progression.

Authors:  Dolores Hambardzumyan; David H Gutmann; Helmut Kettenmann
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

8.  Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.

Authors:  T Kwak; K Drews-Elger; A Ergonul; P C Miller; A Braley; G H Hwang; D Zhao; A Besser; Y Yamamoto; H Yamamoto; D El-Ashry; J M Slingerland; M E Lippman; B I Hudson
Journal:  Oncogene       Date:  2016-09-26       Impact factor: 9.867

9.  In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.

Authors:  Ali Hafez Ali Mohammed El-Far; Seiichi Munesue; Ai Harashima; Akira Sato; Mika Shindo; Shingo Nakajima; Mana Inada; Mariko Tanaka; Akihiko Takeuchi; Hiroyuki Tsuchiya; Hiroshi Yamamoto; Hazem M E Shaheen; Yasser S El-Sayed; Shuhei Kawano; Sei-Ichi Tanuma; Yasuhiko Yamamoto
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

10.  Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma.

Authors:  L Treps; S Edmond; E Harford-Wright; E M Galan-Moya; A Schmitt; S Azzi; A Citerne; N Bidère; D Ricard; J Gavard
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.